deltatrials
Completed NCT00096928

A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)

Sponsor: Genentech, Inc.

Conditions Psoriasis
Updated 8 times since 2017 Last updated: Jul 1, 2015 Started: Mar 31, 2005 Completion: Oct 31, 2009

A observational or N/A phase clinical study on Psoriasis, this trial is completed. The trial is conducted by Genentech, Inc. and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed

  2. Sep 2024 — Sep 2025 [monthly]

    Completed

  3. Jul 2024 — Sep 2024 [monthly]

    Completed

  4. Jan 2021 — Jul 2024 [monthly]

    Completed

  5. Jun 2018 — Jan 2021 [monthly]

    Completed

▶ Show 3 earlier versions

  1. Apr 2018 — Jun 2018 [monthly]

    Completed

    Phase: PHASE4 → None

  2. Feb 2017 — Apr 2018 [monthly]

    Completed PHASE4

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE4

    First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States, Alpharetta, United States, Ann Arbor, United States, Atlanta, United States, Aurora, United States, Aventura, United States, Bakersfield, United States, Bartlett, United States, Baton Rouge, United States, Bay City, United States and 145 more location s